Alivio Therapeutics receives $3.3m from US Department of Defense to support development of IBD drug candidate
pharmafile | October 5, 2020 | News story | Research and Development, Sales and Marketing | Alivio, US, ibd, pharma
The US Department of Defense (DoD) has committed a Technology/Therapeutic Development Award to the value of $3.3 million to biotech firm Alivio Therapeutics to support and galvanise development of the latter’s inflammatory bowel disease (IBD) therapy known as ALV-304.
The funding will help push preclinical research and development into the candidate with the goal of submitting an investigational new drug application. IBD is thought to affect up to three million in the US today.
Alivio’s therapy selectively targets inflamed sites to restore immune homeostasis while avoiding any significant impact on the rest of the body’s immune system. The platform has already been successfully trialed for proof-of-concept in ten different preclinical inflammation models, demonstrating “significant improvements” over untreated controls across a range of efficacy endpoints with very low systemic blood levels.
“Our novel platform technology has the potential to generate inflammation-targeting therapies for the treatment of many acute and chronic inflammatory diseases using biologics, small molecules or drug combinations in an oral formulation,” explained Alivio CEO Brian Leuthner. “IBD as an indication is a great pairing of our technology and an important clinical need; ALV-304 could potentially offer a novel therapeutic option to improve the health of patients living with moderate to severe forms of IBD. We are excited by this potential and the DoD award that will support our efforts to advance ALV-304 into the clinic.”
Matt Fellows
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Cell therapy partnership aims to bring liver disease treatment closer to US patients
Resolution Therapeutics has partnered with the Blood Centers of America (BCA) to support community-based delivery …
